Nantes, June 5, 2023 – 8:00 a.m. CEST – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in phage therapy intended to treat antibiotic-resistant and/or complicated bacterial infections (the “Company”), announces that it has been informed that Akkadian Partners has initiated legal proceedings against Erytech aimed at obtaining the postponement of the vote at the General Meeting on June 23 of the merger with Pherecydes. For further information, please refer to the press release published today by Erytech.
The Company will keep its shareholders informed of the outcome of such legal proceedings, which is part of the campaign of destabilization and denigration that Akkadian is leading respectively with regard to Erytech and Pherecydes.
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.